The vaccine developed by the company and currently undergoing clinical trials is a genetically engineered protein of the surface antigen coronavirus, with a high degree of safety compared to adenovirus and inactivated types of vaccines, the Ministry informed.

“During the negotiations, it was noted that in case of successful completion of all phases of clinical trials, Uzbekistan will have priority in acquiring a vaccine at a minimum price,” the report says.

Specialists from the Ministry of Innovation Development discussed the organization of the vaccination process with Chinese partners and preparations for it. Clinical trials are expected to be conducted on volunteers aged 18 years and older. Before the trials begin, representatives of the People’s Republic of China will conduct a series of trainings on vaccination conditions.